🇺🇸 FDA
Patent

US 9827295

Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase

granted A61KA61K38/47A61K48/00

Quick answer

US patent 9827295 (Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase) held by Regents of the University of Minnesota expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K38/47, A61K48/00, A61P, A61P25/00